Recursion Pharmaceuticals (RXRX) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXRX, but not buy additional shares or sell existing shares.
View RXRX analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month target prices for Recursion Pharmaceuticals' shares. Their RXRX share price forecasts range from $8.00 to $20.00. On average, they anticipate the company's share price to reach $12.40 in the next year. This suggests a possible upside of 43.7% from the stock's current price.
View analysts price targets for RXRX or view top-rated stocks among Wall Street analysts.

Recursion Pharmaceuticals' stock was trading at $7.71 at the start of the year. Since then, RXRX stock has increased by 11.9% and is now trading at $8.63.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RXRX earnings forecast.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) released its earnings results on Monday, May, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company earned $12.13 million during the quarter, compared to analysts' expectations of $15.93 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 57.15% and a negative net margin of 533.45%.

ETFs with the largest weight of Recursion Pharmaceuticals (NASDAQ:RXRX) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), ARK Genomic Revolution ETF (ARKG), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree Artificial Intelligence and Innovation Fund (WTAI), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

(RXRX) raised $306 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO.

Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX."

Recursion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (13.14%), BlackRock Inc. (5.56%), State Street Corp (3.33%), FMR LLC (2.49%), ARK Investment Management LLC (1.87%) and Platinum Investment Management Ltd. (1.45%). Insiders that own company stock include Blake Borgeson, Christopher Gibson, Dean Y Li, Mubadala Investment Co Pjsc, Shafique Virani and Tina Marriott Larson.
View institutional ownership trends.

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RXRX stock can currently be purchased for approximately $8.63.

Recursion Pharmaceuticals (NASDAQ:RXRX) has a market capitalization of $1.66 billion and generates $39.84 million in revenue each year. The company earns $-239,480,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The company employs 400 workers across the globe.

Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The official website for the company is www.recursion.com. The company can be reached via phone at 385-269-0203, via email at investorrelations@recursion.com, or via fax at 801-821-2872.